MARKETABLE SECURITIES |
12 Months Ended |
|---|---|
Sep. 30, 2022 | |
| Investments, Debt and Equity Securities [Abstract] | |
| MARKETABLE SECURITIES | NOTE 4 – MARKETABLE SECURITIES
During the fiscal year ended 2017, the Company acquired shares of common stock of Amarantus BioScience Holdings, Inc. (“AMBS”) with a fair value of $40,980. The AMBS common stock is recorded as marketable securities in the accompanying balance sheets. Its fair value is adjusted every reporting period and the change in fair value is recorded in the statements of operations as unrealized gain or (loss) on marketable securities. During the years ended September 30, 2022 and 2021, the Company recorded $7,300 and $100 of unrealized loss on marketable securities, respectively. As of September 30, 2022 and 2021, the fair value of these shares was $3,700 and $11,000, respectively.
|